To date, direct-to-consumer genetic tests have not been reviewed by the FDA and as a result, we cannot verify that they provide safe and accurate results.
And second, it intends to verify that companies taking "in process" research tax credits for new innovations that might result in a patent are really doing something new--and really qualify for the credit.